YD Bio Ltd (symbol: YDES) is the issuer of record for a Form 4 filing submitted to the SEC. YD Bio Ltd director Kochi Chang acquired 3,135 restricted share units upon vesting on September 30, 2026; the units converted into 3,135 ordinary shares, and the reported direct ordinary-share position after the transaction was 10,965 shares. The RSUs were granted under the YD Bio Limited Equity Incentive Plan on March 31, 2026, with an aggregate target grant date fair value of $60,000, and vest in four equal quarterly installments.
YD Bio Ltd (symbol: YDES) is the issuer of record for a Form 4 filing submitted to the SEC. YD Bio Ltd director Shao-Ta Lu became entitled to 3,135 restricted share units on September 30, 2026, and the units converted into 3,135 ordinary shares. Direct ordinary-share holdings after the conversion were 10,965. The filing also lists 51,151 ordinary shares held indirectly by the director’s spouse. The RSUs had an aggregate target grant-date fair value of $60,000 and vest in four equal quarterly installments beginning March 31, 2026.
YD Bio Ltd (YDES) reports that CEO and director Dr. Ethan Shen purchased 12,700 Ordinary Shares on September 14, 2026 in a transaction reported as a purchase in open market or private transactions at a weighted average price of $3.85 per share. The trades occurred in multiple lots at prices between $3.67 and $3.97 per share. Following this transaction, Dr. Shen is reported to hold 11,258,331 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through a trust structure for which he is the settlor, protector and sole beneficiary; no Rule 10b5-1 trading plan is indicated.
YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported an open-market purchase of 3,100 Ordinary Shares on September 9, 2026 at a weighted average price of $3.93 per share, executed in multiple transactions between $3.80 and $4.09. After this purchase, he holds 11,245,631 Ordinary Shares directly and additional shares indirectly through a trust structure of which he is the beneficial owner.
YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported purchasing 18,378 Ordinary Shares on September 4, 2026, in the open market at a weighted average price of $3.67 per share, with individual trade prices ranging from $3.50 to $3.70.
After this transaction, Dr. Shen holds 11,242,531 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through YD Biopharma Holding Limited and related trust entities, of which he is the beneficial owner. No Rule 10b5-1 trading plan is reported.
YD Bio Limited (YDES) filed a prospectus supplement tied to its Form F-1, covering a mixed registration: 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares registered for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of additional warrants. YD Bio’s ordinary shares trade on Nasdaq Global Market under symbol YDES, with a last reported price of $4.80 on August 28, 2026.
Attached unaudited results for the six months ended June 30, 2026 show revenue of $846,501 versus $204,007 a year earlier and a loss from operations of $3.23 million. A non-cash $9.85 million gain from the change in fair value of warrant liabilities produced net income of $6.70 million and improved total shareholders’ equity from a deficit of $(2.86) million to $4.47 million.
Cash and cash equivalents declined from $6.01 million to $2.66 million, with net cash used in operating activities of $2.82 million. Management states that recurring losses (excluding warrant fair value changes), negative operating cash flows and funding needs raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance of the interim financial statements.
YD Bio Limited (YDES) reported unaudited results for the six months ended June 30, 2026. Revenue rose to US$846,501 from US$204,007 a year earlier, driven mainly by drug and medical product sales in Taiwan and technical service revenue in the United States.
Loss from operations widened to US$(3.23) million, but a US$9.85 million gain from the change in fair value of warrant liabilities produced net income of US$6.70 million (vs. a US$(1.92) million loss). Cash and cash equivalents fell to US$2.66 million from US$6.01 million, with operating activities using US$2.82 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Warrant liabilities declined to US$4.52 million from US$14.99 million, helping turn shareholders’ equity from a US$(2.86) million deficit at December 31, 2025 to positive equity of US$4.47 million at June 30, 2026. There were 70.84 million ordinary shares outstanding at period-end.
YD Bio Limited updates its prospectus covering 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of warrants.
The supplement incorporates a Form 6-K describing the launch of two chrono-nutrition nutraceutical products in Taiwan under a physician-partnership model, in collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. YD Bio’s ordinary shares trade on the Nasdaq Global Market under “YDES,” with a last reported price of $2.51 per share on August 10, 2026.
YD Bio Limited reported the launch of two nutraceutical, chrono-nutrition formulations in Taiwan as part of a new physician-partnership initiative. The products, a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula, were co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute, a physician-led health education platform with 233,000 YouTube subscribers. The company frames this as the first deployment of a repeatable physician-partnership model intended to be capital-light, generate recurring consumer revenue, and build relationships with health-conscious consumers that may support future engagement with its regulated diagnostics and clinical services offerings.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.
The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.